Advertisement

Advertisement

PRLD Stock Latest News

Prelude Therapeutics initiated with a Buy at D. Boral Capital

The FlyPrelude Therapeutics initiated with a Buy at D. Boral Capital

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

PremiumCompany Announcements

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

3d ago

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

PremiumThe Fly

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

8d ago

Prelude Therapeutics Prices Public Offering to Extend Runway

PremiumCompany Announcements

Prelude Therapeutics Prices Public Offering to Extend Runway

14d ago

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

PremiumCompany Announcements

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

15d ago

Prelude Therapeutics presents new preclinical data from PRT13722 study

PremiumThe FlyPrelude Therapeutics presents new preclinical data from PRT13722 study

15d ago

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

Company Announcements

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

20d ago

Prelude Therapeutics announces Charles Morris as chief medical officer

The Fly

Prelude Therapeutics announces Charles Morris as chief medical officer

20d ago

Prelude Therapeutics management to meet with Citizens

PremiumThe Fly

Prelude Therapeutics management to meet with Citizens

2M ago

Prelude Therapeutics Establishes New ATM Equity Offering Facility

PremiumCompany Announcements

Prelude Therapeutics Establishes New ATM Equity Offering Facility

2M ago

Prelude Therapeutics price target raised to $6 from $3 at Citizens

PremiumThe Fly

Prelude Therapeutics price target raised to $6 from $3 at Citizens

2M ago

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

PremiumCompany Announcements

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

2M ago

Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

PremiumThe FlyPrelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

2M ago

Prelude Therapeutics sees cash runway into 2Q27

The Fly

Prelude Therapeutics sees cash runway into 2Q27

2M ago

Prelude Therapeutics Wins FDA IND Clearance for PRT12396

Company Announcements

Prelude Therapeutics Wins FDA IND Clearance for PRT12396

3M ago

Prelude receives FDA clearance for investigational IND for PRT12396

PremiumThe Fly

Prelude receives FDA clearance for investigational IND for PRT12396

3M ago

Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology

PremiumCompany Announcements

Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology

3M ago

Prelude Therapeutics unveils strategic investor presentation on pipelines

PremiumCompany Announcements

Prelude Therapeutics unveils strategic investor presentation on pipelines

4M ago

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

PremiumThe Fly

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

5M ago

Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs

PremiumThe FlyPrelude Therapeutics presents data at 2025 ASH meeting from MPN programs

5M ago

Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges

Company Announcements

Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges

6M ago

Prelude Therapeutics Advances Pipeline and Strengthens Financials

Company Announcements

Prelude Therapeutics Advances Pipeline and Strengthens Financials

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >